Diabetes Contender Faces Second FDA Panel
(MedPage Today) -- An FDA advisory committee will be paying close attention to updated cardiovascular safety analyses of the investigational type 2 diabetes drug dapagliflozin (Farxiga), which has already once been denied approval by the agency.
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news
More News: Cardiology | Cardiovascular | Dapagliflozin | Diabetes | Diabetes Type 2 | Endocrinology | Forxiga | Heart